Kunal R. More
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Kunal R. More has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Amrita Ojha
Department of Immunology and Microbiology, UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, USA
2 shared publications- Cody B. Jackson
Department of Immunology and Microbiology, The Scripps Research Institute, Jupiter, FL, USA
2 shared publications - Hyeryun Choe
Division of Infectious Disease, Boston Children’s Hospital
2 shared publications - Lizhou Zhang
Division of Infectious Disease, Boston Children’s Hospital
2 shared publications Michael Farzan
Division of Infectious Disease, Boston Children’s Hospital, Boston, USA
2 shared publications- Norbert Pardi
Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
2 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 11 October 2023
- Published by Springer Nature in npj Vaccines
- Vol. 8 (1) , 1-14
Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability
During the COVID-19 pandemic, Pfizer-BioNTech and Moderna successfully developed nucleoside-modified mRNA lipid nanoparticle (LNP) vaccines. SARS-CoV-2 spike protein expressed by those vaccines are identical in amino acid sequence, but several key components are distinct. Here, we compared the effect of ionizable lipids, untranslated regions (UTRs), and nucleotide composition of the two vaccines, focusing on mRNA delivery, antibody generation, and long-term stability. We found that the ionizable lipid, SM-102, in Moderna’s vaccine performs better than ALC-0315 in Pfizer-BioNTech’s vaccine for intramuscular delivery of mRNA and antibody production in mice and long-term stability at 4 °C. Moreover, Pfizer-BioNTech’s 5′ UTR and Moderna’s 3′ UTR outperform their counterparts in their contribution to transgene expression in mice. We further found that varying N1-methylpseudouridine content at the wobble position of mRNA has little effect on vaccine efficacy. These findings may contribute to the further improvement of nucleoside-modified mRNA-LNP vaccines and therapeutics.
- 11 October 2023
- Published by Springer Nature in npj Vaccines
- Vol. 8 (1) , 1-14
Top Cited PapersOpen AccessEffect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability
During the COVID-19 pandemic, Pfizer-BioNTech and Moderna successfully developed nucleoside-modified mRNA lipid nanoparticle (LNP) vaccines. SARS-CoV-2 spike protein expressed by those vaccines are identical in amino acid sequence, but several key components are distinct. Here, we compared the effect of ionizable lipids, untranslated regions (UTRs), and nucleotide composition of the two vaccines, focusing on mRNA delivery, antibody generation, and long-term stability. We found that the ionizable lipid, SM-102, in Moderna’s vaccine performs better than ALC-0315 in Pfizer-BioNTech’s vaccine for intramuscular delivery of mRNA and antibody production in mice and long-term stability at 4 °C. Moreover, Pfizer-BioNTech’s 5′ UTR and Moderna’s 3′ UTR outperform their counterparts in their contribution to transgene expression in mice. We further found that varying N1-methylpseudouridine content at the wobble position of mRNA has little effect on vaccine efficacy. These findings may contribute to the further improvement of nucleoside-modified mRNA-LNP vaccines and therapeutics.
- Open Access
- 3 August 2023
- Published by Springer Nature in Research Square
Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability
During the COVID-19 pandemic, Pfizer-BioNTech and Moderna successfully developed nucleoside-modified mRNA lipid nanoparticle (LNP) vaccines. SARS-CoV-2 spike protein expressed by those vaccines are identical in amino acid sequence, but several key components are distinct. Here, we compared the effect of ionizable lipids, untranslated regions (UTRs), and nucleotide composition of the two vaccines, focusing on mRNA delivery, antibody generation, and long-term stability. We found that the ionizable lipid, SM-102, in Moderna’s vaccine performs better than ALC-0315 in Pfizer-BioNTech’s vaccine for intramuscular delivery of mRNA and antibody production in mice and long-term stability at 4°C. Moreover, Pfizer-BioNTech’s 5’ UTR and Moderna’s 3’ UTR outperform their counterparts in their contribution to transgene expression in mice. We further found that varying N1-methylpseudouridine content at the wobble position of mRNA has little effect on vaccine efficacy. These findings may contribute to the further improvement of nucleoside-modified mRNA-LNP vaccines and therapeutics.
- 3 August 2023
- Published by Springer Nature in Research Square
Open AccessEffect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability
During the COVID-19 pandemic, Pfizer-BioNTech and Moderna successfully developed nucleoside-modified mRNA lipid nanoparticle (LNP) vaccines. SARS-CoV-2 spike protein expressed by those vaccines are identical in amino acid sequence, but several key components are distinct. Here, we compared the effect of ionizable lipids, untranslated regions (UTRs), and nucleotide composition of the two vaccines, focusing on mRNA delivery, antibody generation, and long-term stability. We found that the ionizable lipid, SM-102, in Moderna’s vaccine performs better than ALC-0315 in Pfizer-BioNTech’s vaccine for intramuscular delivery of mRNA and antibody production in mice and long-term stability at 4°C. Moreover, Pfizer-BioNTech’s 5’ UTR and Moderna’s 3’ UTR outperform their counterparts in their contribution to transgene expression in mice. We further found that varying N1-methylpseudouridine content at the wobble position of mRNA has little effect on vaccine efficacy. These findings may contribute to the further improvement of nucleoside-modified mRNA-LNP vaccines and therapeutics.